Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Biotech company Celgene
So what: Data showed that secondary malignancies have been found at a higher rate in patients who received Revlimid than those who received a placebo. Analysts think the rates are within historical rates for patients, and the market is overreacting.
Now what: Panicking over data like this is nothing new for drugmakers, but today's reaction looks to have gone a little too far. I look at the dip today as an opportunity to buy a fast-growing drug company that is consistently beating expectations. But keep an eye on data in the next week as the company should provide some clarity given the market's reaction.
Interested in more info on Celgene? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Is the Stock Market Overpriced? Yes -- but Not These 3 Sectors
If you're looking for bargains in a seemingly overheated market, check out stocks in these sectors.
bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results
The company's experimental CAR-T therapy with Celgene Corp. may be a game changer for multiple myeloma.
3 Growth Stocks for the Long Term
You can count on these three to do some heavy lifting for your portfolio for decades to come.